Search the Newsreel

Sellas CEO Angelos Stergiou Says ‘100% Certain’ AI Can Be Used To Beat Cancer

Sellas Life Sciences CEO Angelos Stergiou believes artificial intelligence will be instrumental in curing cancer by enabling more precise and personalized treatments. He stated that AI can significantly shorten the drug development process and help identify patients most likely to respond to specific therapies. …

Solstice Minerals (ASX:SLS): The Gold Explorer Delivering One of the ASX's Most Compelling Yearly Returns

Is SELLAS Life Sciences Group (SLS) Fully Priced As Regal Trial Debate Heats Up?

SELLAS Life Sciences Group (SLS) stock has seen significant momentum amid heated debate surrounding its Regal Phase 3 trial, with CEO Angelos Stergiou noting it's nearing its 80-event trigger, while short-seller Martin Shkreli added public critique. Despite a sharp rise, the stock's high 22.6x …

SLS Stock Whipsaws As Meme Momentum Meets Biotech Reality

SELLAS Life Sciences (SLS) stock has experienced significant volatility, characterized by "meme stock" dynamics with large price swings driven by social media buzz rather than fundamental news. Despite a recent rally and subsequent drop, the company remains a clinical-stage biotech with no meaningful revenue, …

SLS Stock Jumps Ahead Of CEO’s Fox Appearance: Retail Bets AML Readout Could Spark Big Pharma Bidding War

Shares of Sellas Life Sciences (SLS) increased following speculation among retail traders that the final acute myeloid leukemia (AML) readout, coupled with CEO Angelos Stergiou's upcoming Fox appearance, could attract Big Pharma interest. The company's Phase 3 Regal trial for galinpepimut-S (GPS) is nearing …

SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints

Sellas Life Sciences (SLS) stock is experiencing a significant surge as the company approaches a critical Phase 3 AML study readout and prepares for several investor conferences. The Phase 3 Regal study for acute myeloid leukemia is just two events away from final analysis, …

SELLAS Life Sciences Group (NASDAQ:SLS) surge draws attention to $319 million market-cap deficit ahead of REGAL trial results

SELLAS Life Sciences Group (NASDAQ:SLS) saw a 12.3% surge on Friday, reaching $13.19, which highlighted a significant $319 million discrepancy in its market capitalization calculations. This deficit arises from differing share counts used for valuation (weighted average vs. reported outstanding shares), with the higher …

SELLAS Life Sciences (NASDAQ:SLS) Shares Climb 12% as Estimated Equity Value Rises $1.6 Billion Since May

SELLAS Life Sciences (NASDAQ:SLS) saw its shares climb 12.3% on Friday, reaching $13.19, contributing to a $1.62 billion increase in its estimated equity value since May. This rebound follows earlier drops in the week, with the equity value now standing at approximately $2.59 billion. …

Sellas Life (SLS) Climbs 12% Ahead of ‘Potentially Company-Defining’ Clinical Trial Result

Sellas Life Sciences (SLS) stock rose 12% following anticipation of key clinical trial results for its Galinpepimut-S (GPS) treatment for acute myeloid leukemia, which is nearing its pre-specified patient death threshold. Investor enthusiasm is also fueled by speculation of a potential company takeover, evidenced …

Why SELLAS Life Sciences Group (SLS) Stock Is Up Today

SELLAS Life Sciences Group (SLS) stock is up 10.5% today, likely driven by anticipation of results from its pivotal Phase 3 REGAL trial in acute myeloid leukemia, with 78 of 80 required events already occurred. The company's strong liquidity and recent bullish analyst target …

SLS Stock Pops As Price Target Jumps On REGAL Trial Hopes

SELLAS Life Sciences Group Inc. (SLS) stock has seen a significant price target increase from Alliance Global, jumping from $10 to $25 with a reaffirmed Buy rating. This bullish sentiment is largely driven by optimism surrounding the Phase 3 REGAL trial for Galinpepimut-S in …

SLS Stock Climbs As Analyst Upside Targets REGAL Trial

SELLAS Life Sciences Group Inc. (SLS) stock rose over 10% following Alliance Global raising its price target to $25 from $10, driven by optimism around the Phase 3 REGAL trial for Galinpepimut-S in acute myeloid leukemia. The extended timeline for the trial's required deaths …

SLS Stock Jumps Overnight After New Investor Disclosure – Retail Flags ‘Massive’ Options Bet Ahead Of AML Data

Sellas Life Sciences (SLS) stock saw a 1% overnight increase, driven by a new institutional investment from Armstrong Advisory Group, which reported a new position of 380 shares. This rise also follows attention from retail traders who have flagged significant call options activity for …

Solaris Resources Inc Shows Constructive Momentum as Copper Development Story Gains Investor Attention

Solaris Resources Inc. (TSE:SLS): When Will It Breakeven?

Insiders with their considerable ownership were the key benefactors as Solaris Resources Inc. (TSE:SLS) touches CA$1.9b market cap

With a 41% stake, Solaris Resources Inc. (TSE:SLS) insiders have a lot riding on the company

Solaris Resources Inc. (SLS.TO) stock price, news, quote and history